The patent landscape for daridorexant synthesis is complex, involving various chemical processes and intermediates. Patents often claim specific methods of producing daridorexant, as well as the intermediates and crystalline forms used in its manufacture.
What are the key synthesis steps for daridorexant?
The synthesis of daridorexant typically involves several steps to construct the molecule. Patents related to its synthesis detail specific reaction pathways, reagents, and purification methods aimed at achieving high yield and purity. These methods often involve forming the core chemical structure of daridorexant through a series of chemical transformations [1].
When does daridorexant patent exclusivity expire?
The patent exclusivity for daridorexant is a critical factor for potential generic competition. Patent expiry dates are publicly available and can be tracked through resources like DrugPatentWatch.com. Exclusivity periods can be extended through various mechanisms, such as patent term extensions or new patents covering different aspects of the drug, like novel formulations or manufacturing processes [2].
Who holds the primary patents for daridorexant?
The primary patents for daridorexant are held by Idorsia Pharmaceuticals Ltd. These patents cover the composition of matter, methods of use, and manufacturing processes for daridorexant [1].
How are daridorexant patents being challenged?
Patents related to pharmaceuticals, including daridorexant, can be subject to challenges by other companies seeking to enter the market with generic versions. These challenges often occur through patent litigation or by seeking to invalidate existing patents based on prior art or obviousness. The strength and scope of the patent claims are central to these disputes [3].
Can biosimilars be developed for daridorexant?
Daridorexant is a small molecule drug, not a biologic. Therefore, the concept of "biosimilars" does not apply. Instead, generic versions of small molecule drugs are developed. The pathway for generic drug approval involves demonstrating bioequivalence to the reference product [4].
What are the risks associated with daridorexant synthesis patents?
Risks associated with daridorexant synthesis patents include potential infringement claims if a new synthesis method is too similar to an existing patented process. Companies developing generic versions must carefully navigate the patent landscape to avoid infringing on valid patents. The existence of multiple patents covering different aspects of the synthesis can create a more challenging environment for generic manufacturers [3].
How does daridorexant synthesis relate to its clinical use?
The efficiency and cost-effectiveness of the synthesis process can impact the final price and availability of daridorexant for patients. High-purity synthesis is crucial to ensure the safety and efficacy of the drug, as impurities can lead to adverse effects. Regulatory agencies closely scrutinize the manufacturing process to ensure it meets stringent quality standards [4].
Sources:
[1] Idorsia Pharmaceuticals Ltd. (n.d.). Daridorexant patents.
[2] DrugPatentWatch.com. (n.d.). Daridorexant patent information. https://drugpatentwatch.com/
[3] (Information not directly available in provided context, but patent challenges are a general industry practice.)
[4] U.S. Food and Drug Administration. (n.d.). Generic Drugs. https://www.fda.gov/drugs/generic-drugs